New pill takes on advanced cancers: early trial begins
NCT ID NCT06717750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the tablet daily in one of several dose groups, and researchers monitor side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CSCJC3456 tablet
What this could lead to
If this drug proves safe and shows early signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers who have run out of standard therapies.
What could go wrong
This is a very early Phase I trial with only 102 participants. The main goal is safety, not effectiveness. Many cancer drugs that look promising in early testing fail in later, larger studies. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact